Vertex Pharmaceuticals Inc (VRTX) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Vertex Pharmaceuticals Inc  (NASDAQ: VRTX)


Vertex Pharmaceuticals Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Vertex Pharmaceuticals Inc's ROI in the third quarter of 2026?
Vertex Pharmaceuticals Inc achieved a return on average invested assets (ROI) of 16.63 % in its third quarter of 2026, this is above VRTX's average return on investment of 3.92%.
Vertex Pharmaceuticals Incs investments during the 12 months ending in the third quarter of 2026 are valued at $23 billion

ROI decreased relative to the period ending Jun 30 2026, due to the decline in net income.

Within the Healthcare sector 31 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 303, from total ROI ranking in the second quarter of 2026 at 362.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 22.02 % 15.78 % 16.12 % 9.77 % 5.66 %
Y / Y Net Income Change TTM 8.18 % 21.1 % 66.56 % 101.86 % 251.55 %
Investment (TTM) in Millions 27,736 23,485 22,604 21,782 20,387
Return On Investment (TTM) 16.63 % 19.97 % 20.49 % 19.48 % 18.76 %
VRTX's Overall Ranking # 303 # 362 # 332 # 309 # 3012
Seq. Investment Change TTM 8.33 % 4.24 % 4.32 % 3.59 % 2.78 %
Seq. Net Income Change TTM -9.75 % 1.54 % 9.74 % 7.57 % 1.03 %
Net Income (TTM) in Millions 3,976 4,405 4,338 3,953 3,675

VRTX Company Profile >> Back to VRTX Roi Comparisons >> See Annual VRTX Return On Investment



Return On Investment VRTX's Ranking
Within: No.
Industry # 13
Sector # 32
Overall # 303

Return On Investment Statistics
High Average Low
53.02 %
3.92 %
-50.16 %
(Dec 31 2018)   (Jun 30 2011)







Financial Statements
Vertex Pharmaceuticals Inc's III. Quarter Investments $ 27,736 Millions VRTX's Balance sheet
Vertex Pharmaceuticals Inc's III. Quarter Income $ 654 Millions Quarterly VRTX's Income Statement
VRTX's Income by Division See VRTX's Income by Division


VRTX Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 21,782 18,969 19,183 15,409 11,291
Y / Y Investment Growth 14.83 % -1.12 % 24.49 % 36.48 % 14.34 %
Net Income in Millions 3,953 -536 3,620 3,322 2,342
Y / Y Net Income Growth - - 8.96 % 41.84 % -13.63 %
Annual Return On Investment 18.15 % -2.82 % 18.87 % 21.56 % 20.74 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 18.15 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
VRTX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for VRTX's Competitors
Subscribers only: Roi for Vertex Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for VRTX's Customers

Other Ratios
VRTX's Roa VRTX's Inventory Turnover Ratio VRTX's Growth Rates VRTX's Dividend Statistics
VRTX's Profitability Ratios VRTX's Asset Turnover Ratio VRTX's Dividend Growth
VRTX's Roe VRTX's Valuation Ratios VRTX's Financial Strength Ratios VRTX's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Aurinia Pharmaceuticals Inc   45.04 %
Nurix Therapeutics Inc   44.12 %
Medpace Holdings Inc   41.14 %
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Standard Biotools Inc   23.91 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %
Intuitive Surgical Inc   16.30 %
Hca Healthcare Inc   15.54 %
Kiniksa Pharmaceuticals International Plc  15.45 %
Amgen Inc   13.64 %
Carlisle Companies Incorporated  13.64 %
Bristol myers Squibb Company  13.59 %

Date modified: 2026-11-05T14:31:09+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.